PWA
JAZZ icon

Provenance Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Provenance Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$1.24K – 486
2025
Q1 		$1.24K Hold
10
– – ﹤0.01% 451
2024
Q4 		$1.23K Hold
10
– – ﹤0.01% 473
2024
Q3 		$1.11K Hold
10
– – ﹤0.01% 521
2024
Q2 		$1.07K Hold
10
– – ﹤0.01% 439
2024
Q1 		$1.2K Hold
10
– – ﹤0.01% 458
2023
Q4 		$1.23K Buy
10
+1
+11% +$125 ﹤0.01% 506
2023
Q3 		$1.17K Buy
+9
New +$1.2K ﹤0.01% 378

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Provenance Wealth Advisors's JAZZ Position: Q2 2025 in Review

Provenance Wealth Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 10 shares — an estimated $1.24K sold.

Provenance Wealth Advisors first reported a position in JAZZ in Q3 2023 and held it in 7 quarters. The position peaked at $1.24K in Q1 2025. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Provenance Wealth Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Provenance Wealth Advisors sold 10 Jazz Pharmaceuticals shares in Q2 2025, an estimated $1.24K.
  • Provenance Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q3 2023 and held it in 7 quarters.
  • Provenance Wealth Advisors's Jazz Pharmaceuticals position peaked at $1.24K in Q1 2025.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Provenance Wealth Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.